Skip to main content
Fig. 5 | Health Research Policy and Systems

Fig. 5

From: Factors associated with the speed and scope of diffusion of COVID-19 therapeutics in a nationwide healthcare setting: a mixed-methods investigation

Fig. 5

Baricitinib use in the VA as a function of time, with key milestones noted. Proportion of COVID-19 cases that received baricitinib by week among inpatients in the ICU (A), inpatients with severe disease (B), inpatients with mild disease (C) and outpatients (D). Solid lines represent factors that supported adoption, and dashed lines represent factors that favoured de-adoption. Different colours represent different types of information sources (light blue: FDA EUA; dark blue: NIH guideline recommendation; dark green: preprint posting date; purple: publication in peer-reviewed journal; pink: press release)

Back to article page

Health Research Policy and Systems

ISSN: 1478-4505

Contact us